Nyxoah (NASDAQ:NYXH – Get Free Report) and Utah Medical Products (NASDAQ:UTMD – Get Free Report) are both small-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their earnings, risk, analyst recommendations, valuation, institutional ownership, dividends and profitability.
Profitability
This table compares Nyxoah and Utah Medical Products’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Nyxoah | -1,043.93% | -51.68% | -40.11% |
| Utah Medical Products | 34.62% | 12.10% | 11.50% |
Earnings & Valuation
This table compares Nyxoah and Utah Medical Products”s revenue, earnings per share and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Nyxoah | $5.08 million | 50.89 | -$46.77 million | ($1.87) | -5.55 |
| Utah Medical Products | $50.22 million | 4.24 | $16.64 million | $4.27 | 14.70 |
Analyst Ratings
This is a breakdown of recent recommendations for Nyxoah and Utah Medical Products, as reported by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Nyxoah | 0 | 0 | 5 | 0 | 3.00 |
| Utah Medical Products | 0 | 0 | 0 | 0 | 0.00 |
Nyxoah presently has a consensus price target of $17.00, suggesting a potential upside of 63.93%. Given Nyxoah’s stronger consensus rating and higher possible upside, equities analysts plainly believe Nyxoah is more favorable than Utah Medical Products.
Risk and Volatility
Nyxoah has a beta of 1.35, indicating that its stock price is 35% more volatile than the S&P 500. Comparatively, Utah Medical Products has a beta of 0.09, indicating that its stock price is 91% less volatile than the S&P 500.
Insider & Institutional Ownership
69.6% of Utah Medical Products shares are held by institutional investors. 17.1% of Nyxoah shares are held by insiders. Comparatively, 6.6% of Utah Medical Products shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.
Summary
Utah Medical Products beats Nyxoah on 8 of the 14 factors compared between the two stocks.
About Nyxoah
Nyxoah S.A., a medical technology company, focuses on the development and commercialization of solutions to treat sleep disordered breathing conditions. The company’s lead solution comprises Genio system, a CE-Marked, patient-centric, and hypoglossal neurostimulation therapy to treat moderate to severe obstructive sleep apnea. Nyxoah S.A. was incorporated in 2009 and is headquartered in Mont-Saint-Guibert, Belgium.
About Utah Medical Products
Utah Medical Products, Inc. develops, manufactures, and distributes medical devices for the healthcare industry worldwide. It offers fetal monitoring accessories, vacuum-assisted delivery systems, and other labor and delivery tools; DISPOSA-HOOD infant respiratory hoods; and DELTRAN PLUS blood pressure monitoring systems. It also provides GESCO, an umbilical vessel catheters, including DIALY-NATE disposable peritoneal dialysis sets; PALA-NATE silicone oral protection devices; URI-CATH urinary drainage systems; NUTRI-CATH\NUTRI-LOK feeding device; PICC-NATE, a percutaneous intraepithelial central venous catheter; MYELO-NATE lumbar sampling kits; HEMO-NATE disposable filters; and catheterization procedure tray of instruments and supplies. In addition, the company offers LETZ system to excise cervical intraepithelial neoplasia and other lower genital tract lesions; loop, ball, and needle electrodes; FILTRESSE evacuators; other specialty electrodes and supplies, and gynecologic tools; Femcare trocars, cannulae, laparoscopic instruments, and accessories; and EPITOME and OptiMicro electrosurgical devices. Further, it provides Filshie Clip female surgical contraception devices; PATHFINDER PLUS, an endoscopic irrigation devices; suprapubic catheterization; LIBERTY, an urinary incontinence treatment and control systems; ENDOCURETTE, a curette for uterine endometrial tissue sampling; TVUS/HSG-Cath to assess abnormal or dysfunctional uterine bleeding and other abnormalities of uterus; and LUMIN, a tool to manipulate the uterus in laparoscopic procedures. Additionally, it offers DELTRAN, a disposable pressure transducer; high-pressure and piezo-resistive transducer assemblies; and pressure monitoring accessories, components, and other molded parts. It serves neonatal intensive care units, labor and delivery departments, women's health centers in hospitals, outpatient clinics, and physician's offices. The company was incorporated in 1978 and is headquartered in Midvale, Utah.
Receive News & Ratings for Nyxoah Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Nyxoah and related companies with MarketBeat.com's FREE daily email newsletter.
